정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1094 | Withdrawn | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year | Symptomatic COVID-19 Infection Laboratory-Confirmed | Drug: Lopinavir/Ritonavir Drug: Placebo Administration Other: Questionnaire Administration |
Phase 2 | OHSU Knight Cancer Institute, Oregon Health and Science University | OTHER | 0 | All | 18 Years | |
| 1093 | Recruiting | Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS | ARDS | Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use | Phase 2 | Assistance Publique Hopitaux De Marseille | OTHER | 90 | All | 18 Years ~ 80 Years | Assistance Publique Hopitaux de Marseille, Marseille, France |
| 1092 | Completed | Losartan for Patients With COVID-19 Not Requiring Hospitalization | SARS-CoV Infection | Drug: Losartan Other: Placebo |
Phase 2 | University of Minnesota, The Minnesota Foundation | OTHER | 162 | All | 18 Years | Hennepin County Medical Center, Minneapolis, Minnesota, United States M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States University of Minnesota, Minneapolis, Minnesota, United States Mayo Clinic Health System, Rochester, Minnesota, United States |
| 1091 | Completed | Losartan for Patients With COVID-19 Requiring Hospitalization | SARS-CoV Infection | Drug: Losartan Other: Placebo |
Phase 2 | University of Minnesota, Bill and Melinda Gates Foundation | OTHER | 205 | All | 18 Years | University of Florida Health Gainesville, Gainesville, Florida, United States University of Florida Health Jacksonville, Jacksonville, Florida, United States Grady Memorial Hospital, Atlanta, Georgia, United States Henry Ford Hospital, Detroit, Michigan, United States M Health Fairview Ridges Hospital, Burnsville, Minnesota, United States M Health Fairview Southdale Hospital, Edina, Minnesota, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States University of Minnesota, Minneapolis, Minnesota, United States North Memorial Health Hospital, Robbinsdale, Minnesota, United States University of Mississippi Medical Center, Jackson, Mississippi, United States Cooper University Hospital, Camden, New Jersey, United States University of Cincinnati Medical Center, Cincinnati, Ohio, United States |
| 1090 | Terminated | Losmapimod Safety and Efficacy in COVID-19 | COVID-19 | Drug: Losmapimod oral tablet Drug: Placebo oral tablet |
Phase 3 | Fulcrum Therapeutics | INDUSTRY | 52 | All | 50 Years | University of California Irvine - Irvine Medical Center, Irvine, California, United States University of Miami, Miami, Florida, United States University of South Florida, Tampa, Florida, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Memorial Hermann Hospital South West, Houston, Texas, United States University of Texas Health Science Center at Houston, Houston, Texas, United States United Medical Memorial Hospital, Houston, Texas, United States Hospital Universitario Cassiano Antonio de Moraes-HUCAM/Hospital das Clinicas, Vitoria, ES, Brazil Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre, SC, Brazil Hospital Santa Paula, San Paolo, SP, Brazil Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico Nuevo Hospital Civil de Guadalajara, Guadalajara, JC, Mexico JM Research Cuernavaca, Cuernavaca, Morelos, Mexico Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada, S.C., Culiacan, Sinaloa, Mexico Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud Arequipa, Arequipa, AR, Peru |
| 1089 | Recruiting | Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years | COVID-19 | Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1 |
Phase 4 | Sinovac Biotech Co., Ltd | INDUSTRY | 2520 | All | 3 Years ~ 17 Years | Yaliang county Center for Disease Control and Prevention, Xi'an, Shanxi, China |
| 1088 | Active, not recruiting | Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults | COVID-19 | Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) | Phase 4 | Sinovac Research and Development Co., Ltd. | INDUSTRY | 1080 | All | 26 Years ~ 45 Years | Jingliang Wu, Huai'an, Jiangsu, China |